Viatris Inc. has announced positive top-line results from its Phase 3 LYNX-2 trial evaluating MR-142, a phentolamine ophthalmic solution 0.75%, for treating significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision. The trial, conducted under a Special Protocol Assessment with the U.S. FDA, demonstrated that MR-142 met its primary endpoint, showing a ≥15-letter (≥3-line) improvement in mesopic low contrast distance visual acuity compared to placebo. The randomized, placebo-controlled study involved 199 patients and was conducted over a 6-week period. No evidence of tachyphylaxis was observed. The FDA has granted Fast Track designation to MR-142, potentially accelerating its development and review process. A second pivotal study, LYNX-3, is expected to commence soon, with results expected in the first half of 2026.